

Charles R Harrington

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8258527/charles-r-harrington-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

4,003
citations

33
h-index

62
g-index

107
ext. papers

4,599
ext. citations

6.8
avg, IF

5.04
L-index

#	Paper	IF	Citations
94	Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia.. <i>Brain Communications</i> , 2021 , 3, fcab241	4.5	
93	Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297-391) Intermediates. <i>Cells</i> , 2021 , 10,	7.9	3
92	Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
91	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. <i>Frontiers in Neurology</i> , 2021 , 12, 660087	4.1	14
90	Tau Protein Phosphorylated at Threonine-231 is Expressed Abundantly in the Cerebellum in Prion Encephalopathies. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 769-785	4.3	
89	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1517-1531	4.3	2
88	The Neurovascular Unit Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	25
87	Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 1017-1023	4.3	0
86	Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. <i>Brain Communications</i> , 2020 , 2, fcaa033	4.5	5
85	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 553-569	4.3	3
84	National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in Mexico. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 853-862	4.3	1
83	Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 501-519	4.3	11
82	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. <i>Current Alzheimer Research</i> , 2020 , 17, 285-296	3	7
81	Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. <i>Journal of Biological Chemistry</i> , 2020 , 295, 18508-18523	5.4	0
80	Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain. <i>FEBS Letters</i> , 2020 , 594, 944-950	3.8	22
79	Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. <i>Journal of Molecular Biology</i> , 2020 , 432, 4891-4907	6.5	5
78	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2

77	PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020 , 14, 247	6.1	7
76	Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 631-645	4.3	4
75	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, 931-946	4.3	13
74	Increased Cholinergic Response in β Synuclein Transgenic Mice (h- β SynL62). <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1915-1922	5.7	5
73	Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1287-1303	4.3	18
72	Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT). <i>Journal of Molecular Biology</i> , 2018 , 430, 4119-4131	6.5	15
71	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 435-457	4.3	91
70	Alpha-Synuclein transgenic mice, h- β SynL62, display β Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease. <i>Behavioural Brain Research</i> , 2018 , 339, 153-168	3.4	15
69	Monoaminergic neuropathology in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017 , 151, 101-138	10.9	137
68	Assays for the Screening and Characterization of Tau Aggregation Inhibitors. <i>Methods in Molecular Biology</i> , 2017 , 1523, 129-140	1.4	3
67	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases β Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. <i>Frontiers in Molecular Neuroscience</i> , 2017 , 10, 447	6.1	16
66	Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking. <i>Journal of Molecular Biology</i> , 2017 , 429, 3650-3665	6.5	40
65	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet, The</i> , 2016 , 388, 2873-2884	4.0	214
64	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease 2016 , 385-436		1
63	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. <i>Biomolecules</i> , 2016 , 6, 6	5.9	348
62	Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease. <i>Biomolecules</i> , 2016 , 6,	5.9	14
61	O4-08-02: Phase 3 Trial of the TAU Aggregation Inhibitor Leuco-Methylthioninium-Bis (Hydromethanesulfonate) (Lmtm) in Mild to Moderate Alzheimer's Disease 2016 , 12, P351-P352		3
60	Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 705-20	4.3	168

59	Complex disposition of methylthionium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 110-8	4.7	75
58	Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015 , 290, 10862-75	5.4	59
57	The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 2015 , 9, 33	5.1	32
56	Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. <i>Cellular and Molecular Life Sciences</i> , 2015 , 72, 2199-222	10.3	26
55	Effects of oxidized and reduced forms of methylthionium in two transgenic mouse tauopathy models. <i>Behavioural Pharmacology</i> , 2015 , 26, 353-68	2.4	53
54	Tau-aggregation inhibitor therapy for Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014 , 88, 529-39	6	183
53	Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function. <i>Neurobiology of Aging</i> , 2013 , 34, 1380-8	5.6	25
52	The molecular pathology of Alzheimer's disease. <i>Neuroimaging Clinics of North America</i> , 2012 , 22, 11-22, vii	3	40
51	Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2011 , 24, 331-7	2.8	2
50	Chapter 11:Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer's Disease and Other Tauopathies. <i>RSC Drug Discovery Series</i> , 2010 , 210-232	0.6	2
49	Methylthionium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. <i>Psychopharmacology</i> , 2009 , 202, 53-65	4.7	72
48	Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. <i>Scientific World Journal, The</i> , 2009 , 9, 1463-75	2.2	28
47	Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. <i>Acta Neuropathologica</i> , 2008 , 116, 507-15	14.3	33
46	Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus. <i>Acta Neuropathologica</i> , 2005 , 109, 490-6	14.3	5
45	Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. <i>Neuroscience Letters</i> , 2002 , 317, 161-5	3.3	76
44	The Aetiology of Alzheimer's Disease: Diverse Routes into a Common Tau Pathway 2001 , 97-132		1
43	Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease. <i>Journal of Chemical Neuroanatomy</i> , 2001 , 22, 65-77	3.2	47
42	The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies. <i>NeuroReport</i> , 2000 , 11, 297-9	1.7	23

41	Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 490-6	6.5	102
40	Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. <i>Archives of Neurology</i> , 2000 , 57, 236-40		133
39	Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. <i>American Journal of Pathology</i> , 2000 , 157, 623-36	5.8	165
38	Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. <i>European Journal of Human Genetics</i> , 1999 , 7, 659-63	5.3	52
37	Association between Alzheimer's disease and the NOS3 gene. <i>Annals of Neurology</i> , 1999 , 46, 664-7	9.4	94
36	Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. <i>Acta Neuropathologica</i> , 1998 , 95, 154-8	14.3	57
35	Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation. <i>Biochemical Society Transactions</i> , 1998 , 26, S251	5.1	5
34	Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 222, 68-9	3.3	30
33	Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. <i>Gene</i> , 1997 , 204, 165-70	3.8	67
32	Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 288-95	2.6	11
31	Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. <i>Human Genetics</i> , 1997 , 99, 27-31	6.3	22
30	The role of the Maillard reaction in other pathologies: Alzheimer's disease. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11 Suppl 5, 7-12	4.3	33
29	Alterations in tau protein metabolism during normal aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 95-103	2.6	14
28	Inhibitors of the Maillard Reaction. <i>CNS Drugs</i> , 1996 , 6, 167-177	6.7	8
27	Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 11213-8	11.5	427
26	Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1996 , 91, 633-41	14.3	101
25	The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996 , 246, 132-6	5.1	31
24	Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 169-74	2.6	12

23	Changes in a CSF antigen associated with dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995 , 6, 281-5	2.6	2
22	Molecular determinants of paired helical filament assembly and its therapeutic implications in Alzheimer's disease. <i>International Review of Psychiatry</i> , 1995 , 7, 299-338	3.6	1
21	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. <i>International Review of Psychiatry</i> , 1995 , 7, 361-383	3.6	2
20	Authors' response to commentaries. <i>Neurobiology of Aging</i> , 1995 , 16, 423-431	5.6	2
19	Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995 , 16, 433-45	5.6	36
18	Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995 , 16, 409-17; discussion 418-31	5.6	53
17	Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. <i>NeuroReport</i> , 1995 , 6, 1985-8	1.7	61
16	Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995 , 54, 657-63	3.1	20
15	Characterisation of an antibody relevant to the neuropathology of Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 1995 , 9, 47-51	2.5	3
14	Structure, biochemistry and molecular pathogenesis of paired helical filaments in Alzheimer's disease 1995 , 9-II		4
13	Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 1994 , 5, 215-28	2.6	14
12	Presence of axonal paired helical filament-tau in Alzheimer's disease: submicroscopic localization. <i>Journal of Neuroscience Research</i> , 1994 , 38, 664-9	4.4	2
11	Amyloid fibril formation. <i>Nature Biotechnology</i> , 1994 , 12, 848-849	44.5	
10	Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. <i>Lancet, The</i> , 1994 , 343, 993-7	4.0	112
9	Aluminium, tau protein, and Alzheimer's disease. <i>Lancet, The</i> , 1994 , 344, 204-5	4.0	6
8	Glycation. <i>NeuroReport</i> , 1994 , 5, 859-861	1.7	23
7	Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994 , 53, 158-64	3.1	34
6	Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-protein. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993 , 1158, 120-8	4	4

5	Regional Distribution of Paired Helical Filaments and Normal Tau Proteins in Aging and in Alzheimer's Disease with and without Occipital Lobe Involvement. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992 , 3, 61-69	2.6	2
4	Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 5842-6	11.5	68
3	Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. <i>Analytical Biochemistry</i> , 1990 , 186, 285-7	3.1	63
2	Competitive ELISA for the measurement of tau protein in Alzheimer's disease. <i>Journal of Immunological Methods</i> , 1990 , 134, 261-71	2.5	27
1	Biosynthesis of wall teichoic acids in <i>Staphylococcus aureus</i> H, <i>Micrococcus varians</i> and <i>Bacillus subtilis</i> W23. Involvement of lipid intermediates containing the disaccharide N-acetylmannosaminy N-acetylglucosamine. <i>FEBS Journal</i> , 1985 , 153, 639-45		34